Kadota Toshihito | Nippon Boehringer Ingelheim Co. Ltd.
スポンサーリンク
概要
関連著者
-
Kadota Toshihito
Nippon Boehringer Ingelheim Co. Ltd.
-
Onodera Hiroshi
Pharmaceuticals And Medical Devices Agency
-
Akahori Fumiaki
Azabu University
-
Kadota Toshihito
Nippon Boehringer Ingelheim:japan Pharmaceutical Manufacturers Association
-
Kadota Toshihito
Nippon Boehringer Ingelheim Co. Ltd.:jpma
-
Kadota Toshihito
Nippon Boehringer Ingelheim Co. Ltd.:japan Pharmaceutical Manufactures Association (jpma)
-
Unno Takashi
Nippon Organon:safety Evaluation Forum:japan Pharmaceutical Manufacturers Association
-
Unno Takashi
Nippon Organon
-
WATABE Tadashi
Toyama Medical & Pharmaceutical Univ.
-
Onodera Hiroshi
Pharmaceutical And Medical Devices Agency
著作論文
- Question and Answer on Toxicity 2003 : How far have methods for toxicity assessment been harmonized? (WORKSHOP4: QUESTION AND ANSWER ON TOXICITY 2003; HOW FAR HAVE METHODS FOR TOXICITY ASSESSMENT BEEN HARMONIZED?) (Proceedings of the 30th Annual Meeting)
- S11-1 Toxicology on Regulatory Sciences ; Interpretation of Definition and Signiflcance of NOAEL (No Observed Adverse Effect Level) for Pharmaceuticals(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE
- S11-5 "5. Q&A and Discussion"(SYMPOSIUM 11: REGULATORY SCIENCE IN TOXICOLOGY RESEARCH : INTERPRETATION OF DEFINITION AND SIGNIFICANCE OF NOAEL (NON-OBSERVED ADVERSE EFFECT LEVEL) FOR PHARMACEUTICALS)(Proceedings of the 31st Annual Meeting)
- Summary of the workshop "The Pre-Clinical Safety Evaluation of Biotechnology : Derived Pharmaceuticals"(WORKSHOP 1 : THE WAY TOXICITY EVALUATIONS OF BIO-PHARMACEUTICAL PRODUCTS SHOULD BE CONDUCTED (TOXICOLOGICAL QUESTIONS & ANSWERS-ISSUE 2002).ICH-S6)